Objectives

After participating in this educational activity, attendees should be able to:
1. List currently available agents for reversing direct-acting oral anticoagulants (DOACs)

2. Analyze current and emerging data for the treatment of bleeding with andexanet alfa in patients on anti-Xa inhibitors

3. Recommend an appropriate reversal strategy in the treatment of bleeding in a patient on DOAC therapy

Faculty

Kelly Nguyen, PharmD
PGY1 Pharmacy Resident
Pharmacist
Baystate Medical Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.